Editas Medicine, Inc.’s EDIT share price has dipped by 5.16%, which has investors questioning if this is right time to buy.

“Furthermore, the production costs are high and the cells take a long time to prepare, making it inaccessible to most patients,” Zhang says. Instead of the typical alpha beta T cells used in ...